Document Type : Original Article
Authors
- Nashrifa Israt Khanom 1
- Saima Nur 2
- Sheikh Sabrina Mustari 3
- Omme Jamila 4
- Abu Sa A Dat 5
- Md Mehade Hasan 5
- Mushfiquzzaman Mahim 6
- Farhana Faiza Bristy 7
- Nasrin Tamanna 8
- Md.Moshrraf Hossen 9
- Swapan Kumar Das 10
- Tanvir Ahmed 11
- Md. Ashrafuzzaman Sapon 12
- Md. Shafiqul Islam 13
- Md. Monirul Islam 14
1 Division of Pharmacogenomics & Precision Medicine Research, BioIcon Academy, Dhaka, Banglades. Depertment of Theoretical & Computational Chemistry, University of Dhaka, Dhaka, Bangladesh.
2 Division of Pharmacogenomics & Precision Medicine Research, BioIcon Academy, Dhaka, Bangladesh. Department of Biotechnology and Genetic Engineering, University of Development Alternative Dhaka, Bangladesh.
3 Division of Pharmacogenomics & Precision Medicine Research, BioIcon Academy, Dhaka, Bangladesh. Department of Genetic Engineering and Biotechnology, East West University, Dhaka, Bangladesh.
4 Division of Pharmacogenomics & Precision Medicine Research, BioIcon Academy, Dhaka, Bangladesh. Department of Biochemistry and Molecular Biology, Tejgaon College, National University, Dhaka, Bangladesh.
5 Division of Pharmacogenomics & Precision Medicine Research, BioIcon Academy, Dhaka, Bangladesh. Department of Biochemistry and Molecular Biology, Siddheswari College, Dhaka, Bangladesh.
6 Depertment of Pharmacogenomics & Precision Medicine, BioIcon Academy, Dhaka, Bangladesh. Science Group, Dhaka Residential Model College, Dhaka, Bangladesh.
7 Division of Pharmacogenomics & Precision Medicine Research, BioIcon Academy, Dhaka, Bangladesh. Department of Pharmaceutical Sciences, North South University, Dhaka, Bangladesh.
8 Division of Pharmacogenomics & Precision Medicine Research, BioIcon Academy, Dhaka, Bangladesh. Department of Applied Genomics, Kongju National University, Chungcheongnam-do, South Korea. Department of Genetic Engineering and Biotechnology, Islamic University, Kushtia, Bangladesh.
9 Division of Pharmacogenomics & Precision Medicine Research, BioIcon Academy, Dhaka, Bangladesh. Department of Biotechnology, Bangladesh Agricultural University, Mymensingh, Bangladesh. Department of Genetic Engineering and Biotechnology, Islamic University, Kushtia, Bangladesh.
10 Division of Pharmacogenomics & Precision Medicine Research, BioIcon Academy, Dhaka, Bangladesh. Production Department, Eskayef Bangladesh Limited, Dhaka, Bangladesh.
11 Division of Pharmacogenomics & Precision Medicine Research, BioIcon Academy, Dhaka, Bangladesh. Department of Emergency & Outdoor, Islami Bank Central Hospital, Kakrail, Dhaka, Bangladesh.
12 Department of Genetic Engineering and Biotechnology, Islamic University, Kushtia, Bangladesh.
13 Division of Pharmacogenomics & Precision Medicine Research, BioIcon Academy, Dhaka, Bangladesh. Department of Physical Science, Independent University Bangladesh, Dhaka, Bangladesh.
14 Depertment of Pharmacogenomics & Precision Medicine, BioIcon Academy, Dhaka, Bangladesh
Abstract
The aim of this study is to investigate the attitude, beliefs, and perceptions among undergraduate and graduate students toward precession medicine (PM) and pharmacogenomics (PGx) practice. A cross-sectional survey is conducted amongst students from different universities in Bangladesh.The results of the survey showed that the majority of students had a positive attitude towards precision medicine and pharmacogenomics, perceiving it as a means to improve diagnosis and treatment accuracy. Furthermore, many students also expressed a willingness to learn more about precision medicine and pharmacogenomics, suggesting that there is potential for these practices to be utilized in Bangladesh. Particularly in this study, 337 students from life science and relevant programs participated. From this study, it is shown that 84% of graduate students and 74% of undergraduate students thought PM is a promising healthcare model. In addition, 39% of students are highly encouraged to pursue their post-graduation in the subject areas of PGx and PM to support patients. The majority (62%) thought that patient privacy was the ethical concern most closely related to pharmacogenomic testing, while 19% of respondents thought that data confidentiality was the key issue. The results provide insight into the potential of precision medicine and pharmacogenomics in Bangladesh and suggest that further research into the attitudes of healthcare professionals should be conducted in order to take full advantage of the potential of these practices.
Keywords
Kaur, H., Bhattacharyya, A., Kumar, S., Sharma, S.,
Prakash, A., & Medhi, B. Virtual screening and molecular
dynamics study of approved drugs as inhibitors of spike
protein S1 domain and ACE2 interaction in SARS-
CoV-2. Journal of Molecular Graphics and Modelling.
2020;101, 107716.
2.Cheung, N. Y. C., Fung, J. L. F., Ng, Y. N. C., Wong,
W. H. S., Chung, C. C. Y., Mak, C. C. Y., & Chung,
B. H. Y. Perception of personalized medicine,
pharmacogenomics, and genetic testing among
undergraduates in Hong Kong. Human Genomics. 2021
; 15(1), 1–12.
3.Mahmutovic, L., Akcesme, B., Durakovic, C.,
Akcesme, F. B., Maric, A., Adilovic, M., Hamad, N.,
Wjst, M., Feeney, O., & Semiz, S. Perceptions of
students in health and molecular life sciences regarding
pharmacogenomics and personalized medicine. Human
Genomics. 2018; 12(1), 1–15.
4.Saud, K., & Syed, W. Knowledge, Attitude and
Perception of University of Ibadan Pharmacy Students
on Veterinary Pharmacy Practice. Nigerian Journal of
Pharmacy. 2022 ; 56(1).
5.Moses III, H., & Martin, J. B. Academic Relationships
With Industry. Jama.2001 ; 285(7), 933.
6.Dhawan, D., & Padh, H. Pharmacogenomics and
personalized medicine for cancer. In Omics for
Personalized Medicine. 2013.
7.Abou Diwan, E., Zeitoun, R. I., Abou Haidar, L.,
Cascorbi, I., & Khoueiry Zgheib, N. Implementation
and obstacles of pharmacogenetics in clinical practice:
An international survey. British Journal of Clinical
Pharmacology. 2019 ; 85(9), 2076–2088.
8.Relling, M. V., & Evans, W. E. Pharmacogenomics in
the clinic. Nature.2015 ; 526(7573), 343–350.
9.Norton, R. Pharmacogenomics: The Search for
Individualized Therapies. In Drug Discovery Today.
2002 ; (Vol. 7, Issue 21).
10.Robert, F., & Pelletier, J. Exploring the Impact of
Single-Nucleotide Polymorphisms on Translation.
Frontiers in Genetics. 2018 ; 9(October), 1–11.
11.Madsen, B. E., Villesen, P., & Wiuf, C. A periodic
pattern of SNPs in the human genome. Genome
Research. 2007 ; 17(10), 1414–1419.
Nashrifa Israt Khanomet al Pers M J23
12.Reisberg, S., Krebs, K., Lepamets, M., Kals, M., Mägi,
R., Metsalu, K., Lauschke, V. M., Vilo, J., & Milani, L.
Translating genotype data of 44,000 biobank participants
into clinical pharmacogenetic recommendations:
challenges and solutions. Genetics in Medicine. 2019 ;
21(6), 1345–1354.
13.Shepherd, G., Mohorn, P., Yacoub, K., & May, D. W.
Décès suite aux effets indésirables rapportés aux États
Unis en utilisant les statistiques de l’état civil entre
1999-2006. Annals of Pharmacotherapy. 2012 ; 46(2),
169–175.
14.Koutsilieri, S., Tzioufa, F., Sismanoglou, D. C.,
& Patrinos, G. P. (2020). Unveiling the guidance
heterogeneity for genome-informed drug treatment
interventions among regulatory bodies and research
consortia. Pharmacological Research. 2020 ; 153,
104590.
15.Kinsella, M., & Monk, C. NIH Public Access. 2012 ;
23(1), 1–7.
16.Burke, W. Clinical validity and clinical utility of
genetic tests. Current Protocols in Human Genetics,
SUPPL. 2009 ; 60, 1–7.
17.Issa, A. M., & Keyserlingk, E. W. Apolipoprotein
E genotyping for pharmacogenetic purposes in
Alzheimer’s disease: Emerging ethical issues. Canadian
Journal of Psychiatry. 2000 ; 45(10), 917–922.
18.Robertson, J. A. Consent and privacy in pharmacogenetic
testing. Nature Genetics. 2001 ; 28(3).
19.Khan, S., Akter, S., Goswami, B., Habib, A.,
Banu, T. A., Barton, C., Osman, E., Samir, S.,
Arjuman, F., Hasan, S., & Hossain, M. Whole
genome mapping and identification of single nucleotide
polymorphisms of four Bangladeshi individuals and
their functional significance. BMC Research Notes.
2021 ; 14(1), 1–6.
20.Ahammad, I., Hossain, M. U., Rahman, A., Chowdhury,
Z. M., Bhattacharjee, A., Das, K. C., Keya, C. A., &
Salimullah, M. Wave-wise comparative genomic study
for revealing the complete scenario and dynamic nature
of COVID-19 pandemic in Bangladesh. PLoS ONE.
2021 ; 16(9 September), 1–21.
21.Akter, S. (n.d.). Genome sequencing and genetic
characterization of 17 SARS-CoV-2 viruses and spike
protein analyses of isolates from Bangladeshi patients.
Research Square. 2021; 1–20.
22.Rahman, M. M., Kader, S. B., & Rizvi, S. M. S.
Molecular characterization of SARS-CoV-2 from
Bangladesh: implications in genetic diversity, possible
origin of the virus, and functional significance of the
mutations, Heliyon. 2021; 7(8), e07866.
23.Swen, J. J., Nijenhuis, M., van Rhenen, M., de Boer-
Veger, N. J., Buunk, A. M., Houwink, E. J. F., Mulder,
H., Rongen, G. A., van Schaik, R. H. N., van der Weide,
J., Wilffert, B., Deneer, V. H. M., & Guchelaar, H. J.
Pharmacogenetic Information in Clinical Guidelines:
The European Perspective. Clinical Pharmacology and
Therapeutics. 2018; 103(5), 795–801.
24.Volpi, S., Bult, C. J., Chisholm, R. L., Deverka, P. A.,
Ginsburg, G. S., Jacob, H. J., Kasapi, M., McLeod,
H. L., Roden, D. M., Williams, M. S., Green, E. D.,
Rodriguez, L. L., Aronson, S., Cavallari, L. H., Denny,
J. C., Dressler, L. G., Johnson, J. A., Klein, T. E., Leeder,
J. S., Relling, M. V. Research Directions in the Clinical
Implementation of Pharmacogenomics: An Overview of
US Programs and Projects. Clinical Pharmacology and
Therapeutics. 2018; 103(5), 778–786.
25.Bienfait, k., Aparna Chhibber, Jean-Claude
Marshall, Martin Armstrong, Charles Cox, Peter
M.Shaw & Charles Paulding. Current challenges and
opportunities for pharmacogenomics: perspective of the
Industry Pharmacogenomics Working Group (I-PWG).
HumanGenetics. 2022;141. P1165–1173.
26.Cecchin, E., and Gabriele Stocco. Pharmacogenomics
and Personalized Medicine. Genes.2020; 11(6), 679.
27.Guy, J. W., Patel, I., & Oestreich, J. H. Clinical
Application and Educational Training for
Pharmacogenomics. Pharmacy. 2020; 8(3), 163.
28.Nickola, T. J., Green, J. S., Harralson, A. F., & Obrien,
T. J. The current and future state of pharmacogenomics
medical education in the USA. Pharmacogenomics.
2012; 13(12), 1419–1425.
29.Latif, D. A., & McKay, A. B. Pharmacogenetics and
pharmacogenomics instruction in colleges and schools
of pharmacy in the United States. American Journal of
Pharmaceutical Education. 2005; 69(2), 152–156.
30.Zayts, O., & Luo, Z. Commodification and
marketisation of genetic testing through online direct-
to-consumer platforms in Hong Kong. Discourse and
Communication. 2017; 11(6), 630–647.
31.Rafiq, M., Ianuale, C., Ricciardi, W., & Boccia, S.
Direct-to-consumer genetic testing: A systematic review
of european guidelines, recommendations, and position
statements. Genetic Testing and Molecular Biomarkers.
2015; 19(10), 535–547.
32.Campion, M. A., Goldgar, C., Hopkin, R. J., Prows,
C. A., & Dasgupta, S. Genomic education for the
next generation of health-care providers. Genetics in
Medicine. 2019; 21(11), 2422–2430.
33.Learning, K., & Curriculum, A. Science Education.
Physics Today. 1964; 17(11), 94.
34.Hunt, S., Wisocki, P., & Yanko, J. Worry and use of
coping strategies among older and younger adults.
Journal of Anxiety Disorders. 2003; 17(5), 547–560.
35.Chang, E. C. a Test of a General Negativity Hypothesis.
1996; 21(5), 819–822.
36.Brookfield, S. from the SAGE Social Science
Collections . All Rights. Hispanic Journal of Behavioral
Sciences. 1984; 9(2), 183–205.
37.Winkler, E. C., & Wiemann, S. Findings made in gene
panel to whole genome sequencing: data, knowledge,
ethics–and consequences? Expert Review of Molecular
Diagnostics. 2016; 16(12), 1259–1270.
Nashrifa Israt Khanomet al Pers M J24
38.Howard, H. C., & Borry, P. Survey of European clinical
geneticists on awareness, experiences and attitudes
towards direct-to-consumer genetic testing. Genome
Medicine.2013; 5(5), 0–31.
)